\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesThe Central European Research Infrastructure Consortium (CERIC-ERIC) is calling for proposals for coordinated access to more than 60 instruments and support laboratories for research in all fields of materials, biomaterials and nanotechnology. A detailed description of the facilities available in CERIC can be found here.
CERIC is open to researchers from all over the world, free of charge for non-proprietary research. In exchange for the free access, the users are required to publish the results of the experiments, with appropriate references to the CERIC facilities and to the local scientific and technical staff involved (CERIC Scientific Data Policy).
The call for proposals has a two-step application process with the following deadlines:
For all information on the call for proposals, partial support for users’s mobility, what’s new in this call, the two-step application process and the online submission platform VUO, visit the call for proposals page and the announcement in the news section on the CERIC website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
